Corbus Pharmaceuticals Holdings (CRBP) Research & Development (2013 - 2025)

Corbus Pharmaceuticals Holdings has reported Research & Development for 13 years, with the latest figure at $20.9 million in Q3 2025.

• On a quarterly basis, Research & Development rose 93.01% year-over-year to $20.9 million in Q3 2025; TTM through Sep 2025 was $60.5 million, a 98.84% increase from a year earlier, with the FY2024 full-year figure at $32.2 million, up 3.38% from the prior year.
• Research & Development was $20.9 million for Q3 2025 at Corbus Pharmaceuticals Holdings, up from $15.2 million in the prior quarter.
• The five-year high for Research & Development was $20.9 million in Q3 2025, with the low at $380000.0 in Q4 2021.
• Average Research & Development over 5 years is $8.5 million, with a median of $7.0 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Research & Development slumped 97.64% in 2021, then surged 1542.83% in 2022.
• Over 5 years, Research & Development stood at $380000.0 in 2021, then soared by 1542.83% to $6.2 million in 2022, then rose by 11.81% to $7.0 million in 2023, then climbed by 25.89% to $8.8 million in 2024, then soared by 137.4% to $20.9 million in 2025.
• The last three Research & Development figures came in at $20.9 million (Q3 2025), $15.2 million (Q2 2025), and $15.6 million (Q1 2025), per Business Quant data.